X4 stock slips after trial data for lead drug (NASDAQ:XFOR)
2024-06-27
MicroStockHub X4 Pharmaceuticals (NASDAQ:XFOR) traded sharply lower on Thursday after the biotech updated data from an ongoing Phase 2 trial for its lead candidate mavorixafor in chronic neutropenia (CN), a rare blood disorder. Citing a May 24 data cut, the Boston, Massachusetts-based biotech said mavorixafor, which X4 (XFOR) markets asContinue Reading